MX2022009462A - Composiciones útiles para tratar la gangliosidosis gm1. - Google Patents
Composiciones útiles para tratar la gangliosidosis gm1.Info
- Publication number
- MX2022009462A MX2022009462A MX2022009462A MX2022009462A MX2022009462A MX 2022009462 A MX2022009462 A MX 2022009462A MX 2022009462 A MX2022009462 A MX 2022009462A MX 2022009462 A MX2022009462 A MX 2022009462A MX 2022009462 A MX2022009462 A MX 2022009462A
- Authority
- MX
- Mexico
- Prior art keywords
- gangliosidosis
- treating
- vector
- compositions useful
- raav
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
- C12N9/2471—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01023—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062969142P | 2020-02-02 | 2020-02-02 | |
| US202063007297P | 2020-04-08 | 2020-04-08 | |
| US202063063119P | 2020-08-07 | 2020-08-07 | |
| PCT/US2021/015988 WO2021155337A1 (en) | 2020-02-02 | 2021-02-01 | Compositions useful for treating gm1 gangliosidosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022009462A true MX2022009462A (es) | 2022-11-10 |
Family
ID=74867612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022009462A MX2022009462A (es) | 2020-02-02 | 2021-02-01 | Composiciones útiles para tratar la gangliosidosis gm1. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230190966A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4096721A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7874545B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220145838A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115867323A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021213826A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022013914A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3165057A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL294924A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022009462A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI905145B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021155337A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3860659A1 (en) | 2018-10-01 | 2021-08-11 | The Trustees of the University of Pennsylvania | Compositions useful for treating gm1 gangliosidosis |
| WO2023147351A1 (en) * | 2022-01-25 | 2023-08-03 | Regents Of The University Of Minnesota | Crispr-mediated human genome editing with vectors |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103589692B (zh) | 2001-11-13 | 2018-07-24 | 宾夕法尼亚大学托管会 | 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法 |
| US8005620B2 (en) | 2003-08-01 | 2011-08-23 | Dna Twopointo Inc. | Systems and methods for biopolymer engineering |
| WO2005012877A2 (en) | 2003-08-01 | 2005-02-10 | Dna Twopointo Inc. | Systems and methods for antibody engineering |
| EP1668143B1 (en) | 2003-09-30 | 2013-03-20 | The Trustees of The University of Pennsylvania | Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor |
| DE23193606T1 (de) | 2005-04-07 | 2024-02-15 | The Trustees Of The University Of Pennsylvania | Verfahren zur erhöhung der funktion eines aav-vektors |
| US7588772B2 (en) | 2006-03-30 | 2009-09-15 | Board Of Trustees Of The Leland Stamford Junior University | AAV capsid library and AAV capsid proteins |
| US8734809B2 (en) | 2009-05-28 | 2014-05-27 | University Of Massachusetts | AAV's and uses thereof |
| WO2011126808A2 (en) | 2010-03-29 | 2011-10-13 | The Trustees Of The University Of Pennsylvania | Pharmacologically induced transgene ablation system |
| US8927514B2 (en) | 2010-04-30 | 2015-01-06 | City Of Hope | Recombinant adeno-associated vectors for targeted treatment |
| FR2977562B1 (fr) | 2011-07-06 | 2016-12-23 | Gaztransport Et Technigaz | Cuve etanche et thermiquement isolante integree dans une structure porteuse |
| US9719106B2 (en) | 2013-04-29 | 2017-08-01 | The Trustees Of The University Of Pennsylvania | Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof |
| WO2016049230A1 (en) | 2014-09-24 | 2016-03-31 | City Of Hope | Adeno-associated virus vector variants for high efficiency genome editing and methods thereof |
| EP3387138B2 (en) | 2015-12-11 | 2026-05-27 | The Trustees Of The University Of Pennsylvania | Scalable purification method for aav9 |
| MA43968A (fr) * | 2016-02-03 | 2018-12-12 | Univ Pennsylvania | Thérapie génique pour traiter la mucopolysaccharidose de type i |
| RS65241B1 (sr) | 2017-02-28 | 2024-03-29 | Univ Pennsylvania | Vektor adeno-asociranih virusa (aav) iz podgrupe f i njegove upotrebe |
| WO2019222314A1 (en) * | 2018-05-15 | 2019-11-21 | University Of Massachusetts | Raav vectors encoding of lysosomal beta-galactorsidase (glb1) and cathepsin a |
| EP3860659A1 (en) * | 2018-10-01 | 2021-08-11 | The Trustees of the University of Pennsylvania | Compositions useful for treating gm1 gangliosidosis |
-
2021
- 2021-02-01 WO PCT/US2021/015988 patent/WO2021155337A1/en not_active Ceased
- 2021-02-01 BR BR112022013914A patent/BR112022013914A2/pt unknown
- 2021-02-01 TW TW110103642A patent/TWI905145B/zh active
- 2021-02-01 CN CN202180025846.9A patent/CN115867323A/zh active Pending
- 2021-02-01 IL IL294924A patent/IL294924A/en unknown
- 2021-02-01 CA CA3165057A patent/CA3165057A1/en active Pending
- 2021-02-01 AU AU2021213826A patent/AU2021213826A1/en active Pending
- 2021-02-01 MX MX2022009462A patent/MX2022009462A/es unknown
- 2021-02-01 US US17/759,905 patent/US20230190966A1/en active Pending
- 2021-02-01 JP JP2022547042A patent/JP7874545B2/ja active Active
- 2021-02-01 EP EP21711072.5A patent/EP4096721A1/en active Pending
- 2021-02-01 KR KR1020227029939A patent/KR20220145838A/ko active Pending
-
2026
- 2026-04-17 JP JP2026068599A patent/JP2026123078A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TWI905145B (zh) | 2025-11-21 |
| CA3165057A1 (en) | 2021-08-05 |
| TW202140781A (zh) | 2021-11-01 |
| BR112022013914A2 (pt) | 2022-09-13 |
| JP2023513487A (ja) | 2023-03-31 |
| JP7874545B2 (ja) | 2026-06-16 |
| US20230190966A1 (en) | 2023-06-22 |
| WO2021155337A1 (en) | 2021-08-05 |
| JP2026123078A (ja) | 2026-07-29 |
| EP4096721A1 (en) | 2022-12-07 |
| KR20220145838A (ko) | 2022-10-31 |
| IL294924A (en) | 2022-09-01 |
| CN115867323A (zh) | 2023-03-28 |
| AU2021213826A1 (en) | 2022-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR123358A1 (es) | Virus adenoasociado recombinante para el tratamiento de la neurodegeneración de inicio adulto asociada a la grn | |
| CL2021002236A1 (es) | Inserción de vectores de virus adeno-asociados de b-sarcoglicano y el tratamiento de distrofia muscular | |
| CO2022012917A2 (es) | Vectores de genoterapia para tratar enfermedades cardíacas | |
| CL2023001650A1 (es) | Tratamiento de la enfermedad de danon | |
| MX2021005517A (es) | Terapia genica para lipofuscinosis neuronal ceroidea. | |
| CL2020002200A1 (es) | Nuevos vectores del virus adeno-asociado (aav), vectores que tienen desaminación de capside reducida y sus usos. | |
| MX2021013420A (es) | Composiciones utiles en el tratamiento de leucodistrofia metacromatica. | |
| MX2023003699A (es) | Virus adenoasociados para el suministro ocular de genoterapia. | |
| MX2020008932A (es) | Novedosos vectores de virus adenoasociado (aav), vectores de aav que tienen una desamidacion reducida de la capside y usos de estos. | |
| CL2020000295A1 (es) | Métodos de terapia génica del factor viii (fviii) | |
| CO2022002864A2 (es) | Administración de vectores de virus adenoasociado de alfa-sarcoglicano y el tratamiento de la distrofia muscular | |
| CO2021016200A2 (es) | Composiciones útiles para el tratamiento de la enfermedad de pompe | |
| PE20211819A1 (es) | Virus adenoasociado recombinante para el tratamiento de la neurodegeneracion de inicio en adultos asociada a grn | |
| CL2023001876A1 (es) | Proteínas de la cápside viral con especificidad para las células del tejido cardiaco | |
| AR122289A1 (es) | Terapia genética cardíaca con aav para la cardiomiopatía en humanos | |
| CO2025001825A2 (es) | Composición para su uso en el tratamiento de la enfermedad de fabry | |
| BR112022013914A2 (pt) | Composições úteis para tratar gangliosidose gm1 | |
| CO2022017224A2 (es) | Composiciones útiles para el tratamiento de la enfermedad de pompe | |
| CO2023004031A2 (es) | Administración sistémica del vector de virus adenoasociado que expresa el sarcoglucano g y el tratamiento de la distrofia muscular | |
| AR121245A1 (es) | Composiciones útiles para tratar gangliosidosis gm1 | |
| JOP20240264A1 (ar) | تركيبات وطرق لعلاج ضعف السمع غير المرتبط بالعمر في خاضع للعلاج من البشر | |
| CO2022017953A2 (es) | Composiciones útiles en el tratamiento de la enfermedad de krabbe | |
| MX2023008826A (es) | Terapia génica para lipofuscinosis neuronal ceroidea. | |
| AR132694A1 (es) | Métodos de tratamiento de pacientes con hemofilia seropositivos anti-aav | |
| AR108687A1 (es) | Terapia génica para el tratamiento de hemofilia a |